Loading...
Back to narrative

MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses

Global Expansion And Minimally Invasive Care Will Shape Future Progress

MLSS logo
MLSS
AnalystConsensusTarget
Not Invested
Published 07 Apr 2025

Update shared on 04 Dec 2025

Fair value Decreased 11%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-53.8%
7D
12.1%

Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.

What's in the News

  • Milestone Scientific has proposed amending its Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (company filing).
  • On October 8, 2025, the company received a non compliance notice from NYSE American for failing to meet continued listing standards under Sections 1003(a)(ii) and (iii) (NYSE American notice).
  • Milestone Scientific must submit a plan by November 7, 2025, detailing how it will regain compliance, and faces potential delisting if it does not meet exchange requirements by April 8, 2027 (NYSE American notice).
  • Management is evaluating strategic and financial options and intends to submit a compliance plan by the exchange imposed deadline (company statement).

Valuation Changes

  • Fair Value: reduced slightly from 1.13 dollars to 1.00 dollars per share, reflecting more conservative assumptions.
  • Discount Rate: lowered marginally from 7.88 percent to 7.79 percent, indicating a slightly lower perceived risk profile.
  • Revenue Growth: cut meaningfully from about 9.19 percent to 7.41 percent, pointing to slower expected top line expansion.
  • Net Profit Margin: kept effectively stable, edging up from 13.38 percent to 13.39 percent, suggesting unchanged profitability expectations.
  • Future P/E: reduced moderately from about 71.7 times to 66.8 times, implying a somewhat lower valuation multiple on projected earnings.

Have other thoughts on Milestone Scientific?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.